Bu öğeden alıntı yapmak, öğeye bağlanmak için bu tanımlayıcıyı kullanınız: http://hdl.handle.net/11452/32176
Başlık: Potential cost-effectiveness of RSV vaccination of infants and pregnant women in Turkey: An illustration based on Bursa data
Yazarlar: Pouwels, Koen B.
Yeğenoğlu, Selen
McIntosh, E. David
Ünal, Serhat
Postma, Maarten J.
Uludağ Üniversitesi/Tıp Fakültesi/Çocuk Enfeksiyon Hastalıkları Anabilim Dalı.
Bozdemir, Şefika Elmas
Çelebi, Solmaz
Hacımustafaoğlu, Mustafa
36112591400
7006095295
6602154166
Anahtar kelimeler: Science & technology - other topics
Respiratory-syncytial-virus
United-states
High-risk
Infection
Children
Influenza
Mortality
Hospitalization
Prophylaxis
Frequency
Yayın Tarihi: 10-Eyl-2016
Yayıncı: Publication Library Science
Atıf: Pouwels, K. B. vd. (2016). "Potential cost-effectiveness of RSV vaccination of infants and pregnant women in Turkey: An illustration based on Bursa data". Plos One, 11(9).
Özet: Background: Worldwide, respiratory syncytial virus (RSV) is considered to be the most important viral cause of respiratory morbidity and mortality among infants and young children. Although no active vaccine is available on the market yet, there are several active vaccine development programs in various stages. To assess whether one of these vaccines might be a future asset for national immunization programs, modeling the costs and benefits of various vaccination strategies is needed. Objectives: To evaluate the potential cost-effectiveness of RSV vaccination of infants and/or pregnant women in Turkey. Methods: A multicohort static Markov model with cycles of one month was used to compare the costeffectiveness of vaccinated cohorts versus nonvaccinated cohorts. The 2014 Turkish birth cohort was divided by twelve to construct twelve monthly birth cohorts of equal size (111,459 new-borns). Model input was based on clinical data from a multicenter prospective study from Bursa, Turkey, combined with figures from the (inter) national literature and publicly available data from the Turkish Statistical Institute (TUIK). Incremental costeffectiveness ratios (ICERs) were expressed in Turkish Lira (TL) per qualityadjusted life year (QALY) gained. Results Vaccinating infants at 2 and 4 months of age would prevent 145,802 GP visits, 8,201 hospitalizations and 48 deaths during the first year of life, corresponding to a total gain of 1650 QALYs. The discounted ICER was estimated at 51,969 TL (26,220 US $ in 2013) per QALY gained. Vaccinating both pregnant women and infants would prevent more cases, but was less attractive from a pure economic point of view with a discounted ICER of 61,653 TL (31,106 US $ in 2013) per QALY. Vaccinating only during pregnancy would result in fewer cases prevented than infant vaccination and a less favorable ICER. Conclusion: RSV vaccination of infants and/or pregnant women has the potential to be costeffective in Turkey. Although using relatively conservative assumptions, all evaluated strategies remained slightly below the threshold of 3 times the GDP per capita.
URI: https://doi.org/10.1371/journal.pone.0163567
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0163567
http://hdl.handle.net/11452/32176
ISSN: 1932-6203
Koleksiyonlarda Görünür:Scopus
Web of Science

Bu öğenin dosyaları:
Dosya Açıklama BoyutBiçim 
Bozdemir_vd_2016.pdf1.27 MBAdobe PDFKüçük resim
Göster/Aç


Bu öğe kapsamında lisanslı Creative Commons License Creative Commons